NCT01561755View on ClinicalTrials.gov

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

PHASE4TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

HIV-associated Myelopathy

Interventions

DRUG

Intravenous Immunoglobulin

Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®

DRUG

Placebo

Placebo - 2gr/kg over 2 days of saline

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

CSL Behring

INDUSTRY

lead

David M. Simpson

OTHER